Jian Teng, Ph.D., Massachusetts General Hospital one-year 2018-2019 final summary I want to take this opportunity to sincerely thank CBTF for your funding to my proposal of using a subset of quinoline methanol anti-malaria agents in killing pediatric brain cancer cells. This funding helps us get one step closer to our goal. With the funding …
Stephen C. Mack, Ph.D., Baylor College of Medicine, Texas Children’s one-year study, final summary We are grateful for support provided by the CBTF and funders that have allowed us to pursue our project on the characterizing “The Role of MOS Proto-Oncogene in H3.3K27M Diffuse Intrinsic Pontine Glioma”. Diffuse intrinsic pontine glioma (DIPG) remains a fatal …
Kevin Bielamowicz, M.D., Arkansas Research Institute 2016, second year Poor outcomes for children with high grade glioma (HGG) warrant novel therapeutic strategies, and redirecting immune cells can achieve this aim while minimizing side effects to normal cells. Using mathematical modeling in a group of brain tumor samples, we discovered substantial variation between individual cells within …
Claudia Petritsch, Ph.D. Funded 2015, second year BRAF Mutation effects on malignant astrocytoma development and therapy responses. Abstract: CD133+ subpopulations of cells in glioblastoma (GBM) show in vivo resistance to treatment with radiation and temozolomide, and are thought to contribute to therapy evasion and tumor recurrence. Frequent hyperactivation of the MAPK pathway in GBM has …
Marius Wernig, M.D., Ph.D. Stanford University School of Medicine The lysine 27 to methionine substitution in histone variant H3.3 (H3.3-K27M) is the most common mutation in pediatric high grade gliomas. Recent studies have demonstrated that this mutation leads to a global reduction of H3K27 trimethylation in a dominant manner by sequestering an enzymatic subunit of …
The Childhood Brain Tumor Foundation proudly was a Silver Sponsor of the 16th International Symposium on Pediatric Neuro-Oncology, a biennial meeting. The meeting was held June 28 through July 2, 2014. The ISPNO Conference in Singapore was attended by over 900 clinicians and clinical and basic science researchers in neuro-oncology. By design, the conference’s plenary …
Sarah Rush, M.D., University of Denver Two-year funding, 2010-2011 Juvenile pilocytic astrocytomas (JPA) are common tumors of childhood. Despite the high incidence, the biological factors that influence outcomes for these children remain poorly understood. Based on our preliminary data, IMP3 represents a highly specific prognostic marker for JPA allowing for improved prediction of outcome. The aim …
Charles Eberhart, M.D., Ph.D. 2010-2011 funding Diffuse intrinsic pontine gliomas (DIPG) are among the most deadly pediatric brain cancers, with no effective therapies. Unfortunately, few models for these exist, severely limiting our ability to test new treatments for the patients who need them most. The goal of our research proposal is to develop accurate models …
Background Primary CNS tumors are the most common pediatric solid cancer, and account for 23% of malignancy in children under 15 years of age, second only to leukemia. The incidence of newly diagnosed brain tumors in the pediatric population is 3.3 cases per 100,000 children, with 3,000 children diagnosed annually. Brain tumors are also the …
